Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis

Table 3 Univariate Analysis of Clinical Characteristics and Inflammatory Parameters in Correlation with 9 m OS

	Univariate analysis (n = 45)			Multivariate regression (n = 45)
	p value	95% CI	OR	p value	95% CI	OR
Clinical Characteristics
Age (≤ 60 years vs. > 60 years)	0.093	0.093–1.201	0.333
Gender (Male vs. Female)	0.365	0.494–6.810	1.833
BMI	0.226	0.925–1.391	1.134
Smoking status (Never vs. With)	0.865	0.331–2.624	0.929
ECOG performance status (≤ 1 vs. ≥ 2)	0.759	0.312–5.567	1.278
Treatment stage 1st-line vs. 2nd vs. 3rd and more	0.033	0.069–0.892	0.248	0.027	0.057–0.842	0.219
ICIs modalities monotherapy vs. + CT vs. + VEGFR vs. three modes combined	0.305	0.310–1.443	0.669
RT segmentation model (CFRT vs. SBRT)	1.000	-	-
Groups (Irradiated sites)	0.432	0.618–3.088	1.381
Inflammatory Parameters
Delta-MLR	0.801	0.710–1.558	1.052
Delta-NLR	0.456	0.661–2.519	1.290
Delta-PLR	0.768	0.268–2.643	0.842
Delta-SII	0.774	0.447–2.953	1.148
Delta-L	0.306	0.353–27.638	3.125
Delta-M	0.657	0.702–1.752	1.109
Delta-EOS	0.338	0.457–1.309	0.773

Abbreviations: OS Overall Survival, CI Confidence Interval, OR Odds Ratio, BMI Body Mass Index, ICIs Immune Checkpoint Inhibitors, VEGFR Vascular Endothelial Growth Factor Receptor, CT Chemotherapy, CFRT Conventional Fractionated radiotherapy, SBRT Stereotactic Body Radiotherapy, ECOG Eastern Cooperative Oncology Group, MLR Monocyte-to-Lymphocyte Ratio, NLR Neutrophil-to-Lymphocyte Ratio, PLR Platelet-to-Lymphocyte Ratio, SII Systemic Immune-Inflammation Index, L Lymphocyte, M Monocyte, EOS Eosinophils

ISSN: 1480-9222